ClinicalTrials.gg
RecruitingNCT05978492Updated Apr 24, 2025

A Study of TXN10128 in Subjects With Solid Tumors

A Phase 1 interventional study of TXN10128 and Irinotecan in Locally Advanced (Unresectable) or Metastatic Solid Tumors, sponsored by Txinno Bioscience Inc.. Recruiting at 6 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Txinno Bioscience Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Study summary

This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors.

This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.

Read the detailed description

This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part. The study includes dose-escalation and dose-expansion parts across three cohorts: TXN10128 monotherapy (Cohorts A) TXN10128 + Irinotecan (Cohorts B) and TXN10128+ Paclitaxel (Cohorts C).

02

Conditions studied

  • Locally Advanced (Unresectable) or Metastatic Solid Tumors

Keywords

  • ENPP1
  • ENPP1 inhibitor
  • TXN10128
  • TxinnoBio
  • Txinno Bioscience
  • Innate immune
  • STING pathway
03

In context

Lead sponsor

Txinno Bioscience Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects ≥19 years of age at the time of .
  • and/or cytologically confirmed any progressive, locally advanced (unresectable), or solid tumors that have or are refractory following the last and for which prior standard therapy has been ineffective, or standard therapy does not exist or is not considered appropriate.
  • performance status of 0 or 1.
  • of at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Has .
  • Experienced a Grade ≥3 immune-related adverse events (irAE) with prior immunotherapy with the exception of non- laboratory abnormalities.
  • Prior organ transplantation.
  • Known positive (HIV) infection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Cohort A-1

    TXN10128 Monotherapy Dose esclation part

    Drug: TXN10128

  • Experimental
    Cohort B-1

    Combination Therapy with TXN10128 and Irinotecan Dose esclation part

    Drug: TXN10128 · Drug: Irinotecan

  • Experimental
    Cohort C-1

    Combination therapy with TXN10128 and Paclitaxel Dose esclation part

    Drug: TXN10128 · Drug: Paclitaxel

Interventions

  • DrugTXN10128

    TXN10128: Oral administration once daily everyday

  • Intravenous (IV) administration at 150 mg/m2 twice (Day 1 and Day 15) at intervals of 2 weeks in one cycle

  • IV administration at 80 mg/m2 three times (Day 1, Day 8, and Day 15) at intervals of 1 week in one cycle (IV administration at 90 mg/m2 for patients with breast cancer)

06

What researchers measure

Primary outcomes

  1. DLT

    A DLT is defined as any of the following AEs (graded using NCI CTCAE v5.0) whose relationship to TXN10128 cannot be ruled out.

    Time frame: Day 1 up to Day 21 for Cohort A(TXN10128 mono cohort) and Day 1 up to Day 28 for Cohort B,C(TXN10128 combination with Irinotecan or paclitaxel cohort) in dose escalation period

  2. Adverse events (AE)

    Adverse events (AE) defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0 at each dose level

    Time frame: Up to 30 days from end of treatment

Secondary outcomes

  1. Cmax

    The time to reach the maximum observed concentration (time)

    Time frame: Up to 21 days from Day 1 dose

  2. AUC inf

    The area under the concentration-time curve extrapolated to infinity (mass\*time/volume)

    Time frame: Up to 21 days from Day 1 dose

  3. AUC last

    The area under the concentration (AUC) -time curve calculated to the last quantifiable concentration point (mass\* time/volume)

    Time frame: Up to 21 days from Day 1 dose

  4. Tmax

    The time to reach the maximum observed concentration (time)

    Time frame: Up to 21 days from Day 1 dose

  5. T1/2

    Elimination half-life, determined as 0.693/Lambda_z (time)

    Time frame: Up to 21 days from Day 1 dose

  6. Vss

    Volume of distribution during the steady state phase (volume)

    Time frame: Up to 21 days from Day 1 dose

  7. Best overall response (BOR)

    Best overall response will be summarized

    Time frame: Up to 30 days from end of treatment

  8. Progression free survival (PFS)

    The survival function will be estimated using the Kaplan-Meier product limit method. Median duration, with a two-sided Brookmeyer-Crowley 90% confidence interval and Kaplan-Meier estimates of survival proportions will be provided at specified time points.

    Time frame: Up to 30 days from end of treatment

  9. Disease control rate (DCR)

    The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease

    Time frame: Up to 30 days from end of treatment

  10. Duration of Response (DOR)

    Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due to study indication. Estimates will use Kaplan-Meier method

    Time frame: Up to 30 days from end of treatment

  11. Overall response rate (ORR)

    Overall response rate will be summarized with accompanying 90% exact binomial confidence interval (CI).

    Time frame: Up to 30 days from end of treatment

07

Study locations

6 of 6 sites recruiting
  • Chungbuk National University Hospital
    Cheonju, Chungcheongbuk-do 28644, Korea, Republic of
    Recruiting
    • Ki-hyeong Lee, MD, PhD · Contact
    • Ki-hyeong Lee, MD, PhD · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggi-do 13620, Korea, Republic of
    Recruiting
    • SeHyun Kim, MD, PhD · Contact
    • SeHyun Kim, MD, PhD · Principal investigator
  • Gachon University Gil Medical Center
    Incheon, 21565, Korea, Republic of
    Recruiting
    • Joo-Hwan Park, MD, PhD · Contact
    • Joo-Hwan Park, MD, PhD · Principal investigator
  • Seoul National Univ. Hospital
    Seoul, 03080, Korea, Republic of
    Recruiting
    • Do-Youn Oh, M.D., Ph.D. · Contact
    • Do-Youn Oh, M.D., Ph.D. · Principal investigator
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
    Recruiting
    • Min-Hee Ryu, M.D., Ph.D. · Contact
    • Min-Hee Ryu, M.D., Ph.D. · Principal investigator
  • SAMSUNG Medical Center
    Seoul, 06351, Korea, Republic of
    Recruiting
    • Jin Seok Ahn, MD, PhD · Contact
    • Jin Seok Ahn, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Dec 2025, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2023
First posted
Aug 7, 2023
StartActual
Jul 27, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05978492
Lead sponsor
Txinno Bioscience Inc.
Responsible party
Sponsor
First posted
Aug 7, 2023
Start date
Jul 27, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Apr 24, 2025

Study contacts

Eun-Young Kwak, Ph.D.
Contact
bella@txinno.com
82 31 778 8688
Min-Hee Ryu, M.D., Ph.D.
principal investigator · Asan Medical Center
Do-Youn Oh, M.D., Ph.D.
principal investigator · Seoul National University Hospital
Jin Seok Ahn, M.D., Ph.D.
principal investigator · Samsung Medical Center
SeHyun Kim, M.D., Ph.D.
principal investigator · Seoul National University Bundang Hospital
Ki-hyeong Lee, M.D., Ph.D.
principal investigator · Chungbuk National University Hospital
Joo-Hwan Park, M.D., Ph.D.
principal investigator · eoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion